Evidence for Mast Cell Activation in Patients with Therapy-Resistant Irritable Bowel Syndrome
The DOI matches its Crossref record.
Abstract
Neuere Untersuchungen legen eine wesentliche Rolle von Mastzellen in der Pathogenese des Reizdarmsyndroms nahe. Ziel der vorliegenden Pilotstudie war es, die mögliche pathophysiologische Rolle von Mastzellen in Reizdarmpatienten mit einem neuartigen Untersuchungsansatz näher zu beleuchten. An 20 Patienten mit therapierefraktärem Reizdarmsyndrom wurde mit einer validierten Checkliste, die die Identifizierung von Mastzellmediator-vermittelten Symptomen erlaubt, und mit ausgesuchten Surrogatparametern das Vorliegen einer pathologisch gesteigerten Aktivität von Mastzellen mit gesteigerter Mediatorfreisetzung untersucht. Bei 19 der 20 untersuchten Patienten konnten Mastzellmediator-induzierte Symptome festgestellt werden. In Abhängigkeit von der Mastzellaktivität pathologisch veränderte Koagulation- und Finbrinolyseparameter wurden bei 11 von 12 dahingehend untersuchten Patienten gefunden. Ein weiterer Patient hatte einen pathologisch erhöhten Methylhistamingehalt im Urin. Die vorliegenden Befunde geben einen Hinweis auf eine hohe Prävalenz für eine pathologisch gesteigerte systemische Mastzellaktivität bei Patienten mit einem therapierefraktärem Reizdarmsyndrom. Diese Beobachtung passt zu der Vorstellung, dass aktivierte Mastzellen in die Pathophysiologie des Reizdarmsyndroms eingebunden sind. Reizdarmpatienten mit therapierefraktärer Symptomatik könnten demnach therapeutisch von der Gabe mastzellstabilisierender Medikamente oder von Wirkstoffen, die die Mediatorwirkung an den Erfolgsorganen antagonisieren, profitieren.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Molderings, G. J., Brettner, S., Homann, J., & Afrin, L. B. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-10 · Cited by 149
Are mast cells instrumental for fibrotic diseases?
Overed-Sayer, C., Rapley, L., Mustelin, T., & Clarke, D. L. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00174 · Cited by 105
Familial Occurrence of Systemic Mast Cell Activation Disease
Molderings, G. J., Haenisch, B., Bogdanow, M., Fimmers, R., & Nöthen, M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076241 · Cited by 94
“Evidence has been presented that MCAS may be an underlying cause of various frequent clinical presentations; for example, in subsets of patients with fibromyalgia [18,19] and irritable bowel syndrome [20].”
BackgroundSelf-citationAfrin, L. B., Butterfield, J. H., Raithel, M., & Molderings, G. J. (2016) · Annals of Medicine · doi:10.3109/07853890.2016.1161231 · Cited by 74
Self-citationMast Cell Activation Syndrome: A Primer for the Gastroenterologist
Weinstock, L. B., Pace, L. A., Rezaie, A., Afrin, L. B., & Molderings, G. J. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06264-9 · Cited by 59
Self-citation
Metadata
- Authors
- Frieling, T., Meis, K., Kolck, U., Homann, J., Hülsdonk, A., Haars, U., Hertfelder, H.-J., Oldenburg, J., Seidel, H., & Molderings, G.
- Venue
- Zeitschrift für Gastroenterologie
- Publisher
- Georg Thieme Verlag KG
- Published
- 2011-02
- Volume
- 49
- Issue
- 02
- Pages
- 191-194
- ISSN
- 0044-2771 (ISSN-L)
- 1439-7803
- OpenAlex
- W1998540774
- Cited by
- 38
- References
- 0
- FWCI
- 4.37
- Type
- journal article
- Language
- de
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence for Mast Cell Activation in Patients with Therapy-Resistant Irritable Bowel Syndrome. https://app.cochat.ai/papers/10.1055/s-0029-1245707
- The paper
- Frieling, T., Meis, K., Kolck, U., Homann, J., Hülsdonk, A., Haars, U., Hertfelder, H.-J., Oldenburg, J., Seidel, H., & Molderings, G. (2011). Evidence for Mast Cell Activation in Patients with Therapy-Resistant Irritable Bowel Syndrome. Zeitschrift für Gastroenterologie. https://doi.org/10.1055/s-0029-1245707
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.